Saturday, March 25, 2023
ThermoGenesis (NASDAQ: THMO) Prepares Launch of ReadyStart cGMP Suites for Cell & Gene Therapy Companies
ThermoGenesis Holdings, Inc. (NASDAQ: THMO) is engaged as an industry leader in automated cell processing tools and services for cell...
Read more
Ainos (NASDAQ: AIMD) Enters MoU with Merdury to Explore Phase 3 Study of VELDONA
Ainos, Inc. (NASDAQ: AIMD) is engaged as a diversified medical technology company, which is focused on developing innovative point-of-care testing...
Read more
Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion
Provention Bio, Inc. (NASDAQ: PRVB) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development and...
Read more
WeightWatchers (NASDAQ: WW) Announces Acquisition of Sequence in Shift to Obesity Drug Market
WW International, Inc. (NASDAQ: WW), or WeightWatchers, describes itself as a human-focused technology company that offers a “proven, science-based, clinically...
Read more
TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company
TCR2 Therapeutics, Inc. (NASDAQ: TCRR) operates as a clinical-stage immunotherapy company, which is focused on the research and development of...
Read more
Altamira Therapeutics’ (NASDAQ: CYTO) Clinical Data on Bentrio Showing Strong Nasal Residence and Rheological Properties
Altamira Therapeutics, Ltd. (NASDAQ: CYTO) is engaged within the research and development of RNA-based therapies for extrahepatic targets and unmet...
Read more
FDA Grants Approval of Reata Pharmaceuticals’ (NASDAQ: RETA) SKYCLARYS Drug, Making the First and Only Drug for Friedreich’s Ataxia
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is engaged as a biopharmaceutical company, which is focused on the research, development and commercialization...
Read more
Cardio Diagnostics (NASDAQ: CDIO) Unveils Innovative Blood Test to Detect Early Stages of Coronary Heart Disease
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) is engaged as an artificial intelligence-driven precision cardiovascular medicine company, which is focused on...
Read more
Timber Pharmaceuticals (NYSE American: TMBR) Granted Orphan Drug Designation in Europe for TMB-001
Timber Pharmaceuticals, Inc. (NYSE American: TMBR) is engaged as a clinical-stage biopharmaceutical company, which is focused on the development and...
Read more
Ocean Biomedical (NASDAQ: OCEA) Skyrockets 324% After Announcing Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors Shown to Kill Glioblastoma & Melanoma Cancer Cells
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a Rhode Island-based biopharmaceutical company, which is focused on the development and commercialization of...
Read more
